Clinicopathological Features and Prognostic Outcomes of Papillary Renal Cell Carcinoma

被引:5
作者
Qian, Xiaoyuan [1 ]
Wan, Junlai [2 ]
Qian, Can [3 ]
Zhang, Jiaqiao [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Urol, Tongji Med Coll, 1095 Jiefang Ave, Wuhan, Hubei, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Orthoped, Tongji Med Coll, Wuhan, Peoples R China
[3] Army Mil Med Univ, Southwest Hosp, Dept Tradit Chinese Med & Rheumatol, Chongqing, Peoples R China
来源
INTERNATIONAL JOURNAL OF GENERAL MEDICINE | 2021年 / 14卷
基金
中国国家自然科学基金;
关键词
papillary renal cell carcinoma; clinical features; pathological features; prognosis; HISTOLOGIC SUBTYPES; SURVIVAL; TYPE-1;
D O I
10.2147/IJGM.S340569
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Although papillary renal cell carcinoma (pRCC) is the second common renal malignant tumor, the current understanding of pRCC is poor. This study aims to explore the clinicopathological features and prognostic factors of pRCC. Methods: From August 2007 and August 2017, 87 patients diagnosed with pRCC by postoperative pathology were enrolled. The clinicopathological features between type1 pRCC and type2 pRCC were compared by Chi-square test, Fisher's exact test, or t-test. The Kaplan-Meier method was performed to estimate progression-free survival (PFS). Univariate and multivariate cox regression models were used to verify the prognostic factors. Results: Of the 87 cases, the median tumor diameter was 5.3cm. Twenty-nine patients were diagnosed with type1 pRCC and 58 patients with type2 pRCC. According pathological stage, 59 (67.8%) cases were in pT1 stage, 19 (21.8%) in pT2 stage, and 9 (10.4%) in pT3 stage. WHO/ISUP pathological grade revealed that 56 (64.4%) patients were in grade I, 17 (19.5%) in grade II, 7 (8.05%) in grade III, and 7 (8.05%) in grade IV. The median follow-up time was 57.0months, and the 1-, 3-year PFS was 95.4%, and 80.8%, respectively. For type1 and type2 pRCC, 3-years PFS was 93.0% and 74.9%, respectively. Survival of type1 pRCC was better than that of type2 (P=0.027). Patients with late pT stage, lymph node metastasis, distant metastasis, high pathological grade, and large size exhibited worse survival. pTNM stage, pathological grade, and tumor types were potentially related to prognosis for PFS. However, an independent prognostic factor affecting PFS was not found in multivariate regression models. For patients with the pT1 stage, nephron-sparing surgery (NSS) and radical nephrectomy (RN) did not affect the PFS, ignoring tumor types (P=0.45). Conclusion: Type2 pRCC is more than type1 pRCC and has an advanced TNM stage and a higher pathological grade. For patients with pRCC with the pT1 stage, the outcome of NSS is not inferior to that of RN.
引用
收藏
页码:7523 / 7531
页数:9
相关论文
共 21 条
  • [1] Papillary Renal Cell Carcinoma (PRCC): An Update
    Akhtar, Mohammed
    Al-Bozom, Issam A.
    Al Hussain, Turki
    [J]. ADVANCES IN ANATOMIC PATHOLOGY, 2019, 26 (02) : 124 - 132
  • [2] Papillary (chromophil) renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases
    Amin, MB
    Corless, CL
    Renshaw, AA
    Tickoo, SK
    Kubus, J
    Schultz, DS
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (06) : 621 - 635
  • [3] The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery
    Bigot, Pierre
    Bernhard, Jean-Christophe
    Gill, Inderbir S.
    Vuong, Nam Son
    Verhoest, Gregory
    Flamand, Vincent
    Reix, Boris
    Suer, Evren
    Gokce, Ilker
    Beauval, Jean Baptiste
    Nouhaud, Francois Xavier
    Eto, Masatoshi
    Baco, Eduard
    Matsugasumi, Toru
    Chowaniec, Yvonne
    Rigaud, Jerome
    Lenormand, Claire
    Pfister, Christian
    Hetet, Jean Francois
    Ploussard, Guillaume
    Roupret, Morgan
    Leon, Priscilla
    El Bakri, Adnan
    Larre, Stephane
    Tillou, Xavier
    Doerfler, Arnaud
    Descazeaud, Aurelien
    Koutlidis, Nicolas
    Schneider, Alexandre
    Sebe, Philippe
    Ingels, Alexandre
    Azzouzi, Abdel Rahmene
    Soulie, Michel
    Mejean, Arnaud
    Bensalah, Karim
    Patard, Jean-Jacques
    [J]. WORLD JOURNAL OF UROLOGY, 2016, 34 (03) : 347 - 352
  • [4] Papillary renal cell carcinoma: correlation of tumor grade and histologic characteristics with clinical outcome
    Cornejo, Kristine M.
    Dong, Fei
    Zhou, Amy G.
    Wu, Chin-Lee
    Young, Robert H.
    Braaten, Kristina
    Sadow, Peter M.
    Nielsen, G. P.
    Oliva, Esther
    [J]. HUMAN PATHOLOGY, 2015, 46 (10) : 1411 - 1417
  • [5] Delahunt B, 1997, MODERN PATHOL, V10, P537
  • [6] Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases
    Delahunt, B
    Eble, JN
    McCredie, MRE
    Bethwaite, PB
    Stewart, JH
    Bilous, AM
    [J]. HUMAN PATHOLOGY, 2001, 32 (06) : 590 - 595
  • [7] Grading of renal cell carcinoma
    Delahunt, Brett
    Eble, John N.
    Egevad, Lars
    Samaratunga, Hemamali
    [J]. HISTOPATHOLOGY, 2019, 74 (01) : 4 - 17
  • [8] Ha Yun-Sok, 2017, Clin Genitourin Cancer, V15, pe181, DOI 10.1016/j.clgc.2016.07.020
  • [9] Histopathology of Surgically Treated Renal Cell Carcinoma: Survival Differences by Subtype and Stage
    Keegan, Kirk A.
    Schupp, Clayton W.
    Chamie, Karim
    Hellenthal, Nicholas J.
    Evans, Christopher P.
    Koppie, Theresa M.
    [J]. JOURNAL OF UROLOGY, 2012, 188 (02) : 391 - 397
  • [10] Is there a Role of the Histologic Subtypes of Papillary Renal Cell Carcinoma as a Prognostic Factor?
    Ku, Ja Hyeon
    Moon, Kyung Chul
    Kwak, Cheol
    Kim, Hyeon Hoe
    Lee, Sang Eun
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (10) : 664 - 670